Pfizer Inc., et al. v. Sandoz Inc., et al., C.A. No. 13-1110-GMS, April 20, 2016.

Sleet, J. The court provides post-trial rulings that the asserted claims of the patents-in-suit are not invalid due to obviousness.

This is an ANDA case concerning fesoterodine fumerate extended release tablets. A 4-day trial was held July 13 through July 16, 2015. The court finds that the fatal flaw in defendants’ compound theory is that their experts did not analyze the full field of overactive bladder treatments to determine what would qualify as a lead compound. Even if the court found that it would have been obvious to create a new HMT prodrug, the court does not find that it would have been obvious to obtain the final chemical structure of fesoterodine. The court finds that none of the asserted claims are invalid due to obviousness. The court does not address secondary considerations.